Tolvaptan

Generic Name
Tolvaptan
Brand Names
Jinarc, Jynarque 45/15 Carton, Samsca, Tolvaptan Accord, Xeljanz
Drug Type
Small Molecule
Chemical Formula
C26H25ClN2O3
CAS Number
150683-30-0
Unique Ingredient Identifier
1E2497LPNY
Background

Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.

Indication

Treatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure, SIADH, and cirrhosis.

Associated Conditions
Autosomal Dominant Polycystic Kidney Disease （ADPKD), Symptomatic euvolemic Hyponatremia, Symptomatic hypervolemic Hyponatremia
Associated Therapies
-
Clinical Trials
Related News

To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks

Phase 4
Recruiting
Conditions
Rheumatoid Arthritis
Interventions
Drug: Glucocorticoid
Drug: Tofacitinib
First Posted Date
2022-11-04
Last Posted Date
2022-11-04
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
230
Registration Number
NCT05606107
Locations
🇨🇳

Jiaxing Central Hospital, Jiaxing, China

🇨🇳

Zhuji People's Hospital, Zhuji, China

🇨🇳

Changxing Country People's Hospital, Changxing, China

and more 2 locations

Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH

First Posted Date
2022-10-06
Last Posted Date
2022-10-06
Lead Sponsor
Chinese Pulmonary Vascular Disease Research Group
Target Recruit Count
100
Registration Number
NCT05569655
Locations
🇨🇳

center of pulmonary vascular disease, Fuwai hospital, Beijing, China

Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis

First Posted Date
2022-08-04
Last Posted Date
2022-08-04
Lead Sponsor
CAGE Bio Inc.
Target Recruit Count
40
Registration Number
NCT05487963

Real-world Effectiveness of Tofacitinib on Ulcerative Colitis Associated Spondyloarthropathy

First Posted Date
2022-06-24
Last Posted Date
2022-06-24
Lead Sponsor
Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)
Target Recruit Count
100
Registration Number
NCT05431283
Locations
🇮🇹

IBD Unit, Department of Internal Medicine, "Villa Sofia-Cervello" Hospital, Palermo, Italy

Postoperative Tolvaptan Use in Left Ventricular Assist Device Implantation Patients

First Posted Date
2022-06-07
Last Posted Date
2022-06-07
Lead Sponsor
University of Chicago
Target Recruit Count
28
Registration Number
NCT05408104
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies

Phase 2
Recruiting
Conditions
Idiopathic Inflammatory Myopathies
Interventions
Drug: tofacitinib
First Posted Date
2022-06-02
Last Posted Date
2022-10-12
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
10
Registration Number
NCT05400889
Locations
🇨🇳

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing, China

Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events

First Posted Date
2022-04-06
Last Posted Date
2023-11-18
Lead Sponsor
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Target Recruit Count
30
Registration Number
NCT05313620
Locations
🇪🇸

Hospital Universitario de La Princesa, Madrid, Spain

Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.

First Posted Date
2022-02-18
Last Posted Date
2023-04-27
Lead Sponsor
National Institute of Respiratory Diseases, Mexico
Target Recruit Count
60
Registration Number
NCT05246293
Locations
🇲🇽

Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Mexico City, Tlalpan, Mexico

The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis

Phase 2
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: TLL-018
Drug: Tofacitinib
First Posted Date
2021-11-24
Last Posted Date
2023-09-05
Lead Sponsor
Hangzhou Highlightll Pharmaceutical Co., Ltd
Target Recruit Count
101
Registration Number
NCT05133297
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis

Not Applicable
Not yet recruiting
Conditions
Ulcerative Colitis
Interventions
Drug: Cyclosporine
Drug: Tofacitinib
First Posted Date
2021-11-08
Last Posted Date
2023-03-29
Lead Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Target Recruit Count
96
Registration Number
NCT05112263
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy